Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib with Chemoradiotherapy for Esophageal Adenocarcinoma
NCT00493025Phase 2Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Apr 2005
- Primary completion
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gefitinib in esophageal adenocarcinoma (EAC) and gastroesophageal junction adenocarcinoma, sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Pathologic Complete Response Rate at 5 years. Started Apr 2005; status: terminated.
02
Drugs
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT00493025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00493025.